DUALITYBIO-B (09606) rose more than 13% intraday, extending gains to 11.1% by press time at HK$314.4, with a turnover of HK$573 million. The company recently announced its board's resolution to pursue a listing on the STAR Market, subject to market conditions, further board approval, shareholder approval, and regulatory clearance. Notably, DUALITYBIO-B debuted on the Hong Kong Stock Exchange's main board on April 15 this year, raising over HK$1.5 billion in its IPO—one of the largest 18A chapter listings in recent years. According to research, rapid innovation in ADC technology has driven significant deal activity. The firm has secured multiple licensing and collaboration agreements with global leaders including BioNTech, BeiGene, Adcendo, GSK, and Avenzo. Its confirmed BD revenue for H1 2023/2024/2025 totaled RMB1.781 billion, RMB1.937 billion, and RMB1.227 billion, respectively, with cumulative deal value surpassing $6 billion.